

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2014261336 B2**

(54) Title  
**Oral dosing of GLP-1 compounds**

(51) International Patent Classification(s)  
**A61K 38/26** (2006.01)

(21) Application No: **2014261336**

(22) Date of Filing: **2014.05.02**

(87) WIPO No: **WO14/177683**

(30) Priority Data

(31) Number  
**13166205.8**

(32) Date  
**2013.05.02**

(33) Country  
**EP**

(43) Publication Date: **2014.11.06**

(44) Accepted Journal Date: **2019.02.28**

(71) Applicant(s)  
**Novo Nordisk A/S**

(72) Inventor(s)  
**Nielsen, Flemming Seier;Sauerberg, Per**

(74) Agent / Attorney  
**Shelston IP Pty Ltd., L 9 60 Margaret St, Sydney, NSW, 2000, AU**

(56) Related Art  
**WO 2008033888 A2**  
**US 20130053311 A1**  
**EP 2565202 A1**  
**STEINERT et al., " Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects "Am.J.Clin.Nutr., (2010), Vol.92, pages 810 - 817**